Related Experiment Video

Updated: Jun 26, 2026

Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

The European paediatric initiative: 1 year of experience

Agnès Saint-Raymond1, Nathalie Seigneuret

  • 1Scientific Advice, Paediatrics, and Orphan Drugs Sector, European Medicines Agency, London, UK. paediatrics@emea.europa.eu

Paediatric Drugs
|January 9, 2009
PubMed

Insights

The European Regulation on medicines for pediatric use, enacted in 2007, significantly alters pediatric drug development. It aims to improve the availability and information on children's medicines through ethical research.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Regulatory Science

Background:

  • Medicines for pediatric use require specific development pathways.
  • Previous approaches to pediatric drug development were often insufficient.
  • Ethical considerations are paramount in pediatric research.

Purpose of the Study:

  • To outline the impact of the European Regulation on pediatric medicine development.
  • To highlight the regulation's role in enhancing pediatric drug availability and information.
  • To emphasize the importance of high-quality, ethical research in this field.

Main Methods:

  • Analysis of the European Regulation on medicines for pediatric use.
  • Review of regulatory changes impacting pediatric drug development.
  • Examination of the framework for ethical research in pediatrics.

Main Results:

  • The regulation mandates a structured approach to pediatric medicine development.
  • It incentivizes pharmaceutical companies to conduct pediatric studies.
  • Increased availability of data and medicines for children is anticipated.

Conclusions:

  • The European Regulation represents a significant advancement in pediatric pharmacotherapy.
  • It is expected to lead to better-informed and more accessible treatments for children.
  • The regulation underscores a commitment to ethical and rigorous pediatric research.

More Related Videos

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

Measuring the Confluence of iPSCs Using an Automated Imaging System11:39

Measuring the Confluence of iPSCs Using an Automated Imaging System

Published on: June 10, 2020

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...